This is an aggregated industry headline. Read the full story at FierceBiotech →
Spyre spies another edge for UC ambitions with midstage win for anti-TL1A antibody
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients' Robart's Histopathology Index (RHI) scores by week 12.
By FierceBiotech
· Jun 16, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Shionogi's "Got the Call, Make the Call" campaign for COVID antiviral Xocova kicks off with a TV ad depicting …
The WeekFierceBiotech ↗
Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sle…
The WeekBriefing
FDA’s July 30 notice sets FY 2027 PDUFA fees below FY 2026 levels for clinical-data applications, non-clinical…